Frank Rimerman Advisors
VRTX icon

Frank Rimerman Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Frank Rimerman Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.76M Sell
3,365
-8
-0.2% -$4.1K 0.1% 161
2026
Q2 		$1.68M Buy
3,373
+56
+2% +$24.8K 0.09% 165
2026
Q1 		$1.48M Buy
3,317
+35
+1% +$16.3K 0.1% 167
2025
Q4 		$1.49M Buy
3,282
+162
+5% +$69.8K 0.09% 169
2025
Q3 		$1.22M Sell
3,120
-126
-4% -$52.7K 0.08% 200
2025
Q2 		$1.45M Sell
3,246
-304
-9% -$140K 0.1% 155
2025
Q1 		$1.72M Buy
3,550
+278
+8% +$130K 0.14% 119
2024
Q4 		$1.32M Sell
3,272
-2,036
-38% -$944K 0.1% 151
2024
Q3 		$2.47M Sell
5,308
-1
-0% -$480 0.18% 101
2024
Q2 		$2.49M Buy
5,309
+5,297
+44,142% +$2.3M 0.18% 96
2024
Q1 		$5.02K Hold
12
– – ﹤0.01% 208
2023
Q4 		$4.88K Buy
+12
New +$4.43K ﹤0.01% 201

Other funds holding VRTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $59.1B AUM 41.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Frank Rimerman Advisors's VRTX Position: Q3 2026 in Review

Frank Rimerman Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 0.24% in Q3 2026, selling an estimated $4.1K and leaving 3,365 shares worth $1.76M. The position accounts for 0.1% of the portfolio, ranked #161.

Frank Rimerman Advisors first reported a position in VRTX in Q4 2023 and has held it in 12 quarters since. The position peaked at $2.49M in Q2 2024. 1,161 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Frank Rimerman Advisors held 3,365 shares of Vertex Pharmaceuticals worth $1.76M as of Q3 2026.
  • Frank Rimerman Advisors sold 8 Vertex Pharmaceuticals shares in Q3 2026, an estimated $4.1K.
  • Vertex Pharmaceuticals made up 0.1% of Frank Rimerman Advisors's portfolio in Q3 2026, its #161 holding.
  • Frank Rimerman Advisors first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 12 quarters since.
  • Frank Rimerman Advisors's Vertex Pharmaceuticals position peaked at $2.49M in Q2 2024.
  • 1,161 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Frank Rimerman Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.